New Delhi: Dr Krishna Ella, founder and chairperson of Bharat Biotech, on Wednesday explained how negative publicity led to the delay in getting Covaxin emergency use list (EUL) by the World Health Organization (WHO).
Scientist Krishna Ella is also the managing director of a Hyderabad-based biotechnology company.
Speaking at the Times Now Summit 2021, Dr Krishna Ella elaborated on the hurdles in WHO approval of Covaccine, “We have 5 vaccines that are WHO pre-qualified so we knew it well, we know how to do it.But the problem is many media people who are negative, they also wrote scientific journals to investigate any death in Bhopal.It was due to suicide but vaccine was blamed for it.
“The way conflicting things happen has hurt us even more. I want people to understand that instead of criticizing just ask us, we will tell the truth. But forming our own opinion that hurt us very badly – which delayed, some process. Were our publications delayed or our WHO pre-qualification delayed because they have to investigate a lot of things… we are very transparent, we are truthful and we won the game,” he said, adding that How negativity harms various processes for Covaxin.
Read also | ‘Har Ghar Dastak’ campaign: Mandaviya to hold meeting with state health ministers on COVID wax drive
When asked about the reason for the negative publicity, the Bharat Biotech founder replied: “When the Prime Minister took the vaccine, he immediately said this is BJP’s vaccine, this is Modi’s vaccine. All kinds of synonyms. We are scientists, we don’t understand politics.”
After a long wait, WHO on 3 November granted Emergency Use List (EUL) to India’s indigenous vaccine Covaxin.
WHO said its technical advisory group has determined that Bharat Biotech’s vaccine meets WHO’s standards for protection against COVID-19.
“The Technical Advisory Group, convened by WHO and composed of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against COVID-19, that the benefits of the vaccine outweigh the risks. There is more and the vaccine could be used,” WHO tweeted.
Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) and recommends administering the vaccine in two doses, with a dosing interval of four weeks, to all groups aged 18 years and over Went.
See below health equipment-
Calculate your body mass index (BMI)
,